Erlotinib, an oral EGFR-TKI, is currently widely used as an effective targeted therapy for patients with non-small cell lung cancer (NSCLC) and pancreatic cancer[1–2,9–10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.